Insmed Still Waiting, Despite FDA Lifting Hold On Arikace
This article was originally published in The Pink Sheet Daily
The company can now return to clinical trials in one indication for its lead compound, but it is still in discussions with FDA on a hold for a second indication.
You may also be interested in...
Transave execs will run new company focused on reformulation of amikacin for lung infections in cystic fibrosis patients.
A virtually broke biotech finds itself flush with cash while a major pharma's recently launched follow-on biologics play now enjoys an expanded pipeline and increased research and manufacturing capabilities - that's the outcome of a transaction labeled "a win/win for both parties" by Insmed CEO Geoffrey Allan
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.